Allianz Asset Management
HRTX icon

Allianz Asset Management’s Heron Therapeutics HRTX Stock Holding History

Allianz Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-155,085
Closed -$887K – 2315
2022
Q1 		$887K Sell
155,085
-60,559
-28% -$443K ﹤0.01% 1902
2021
Q4 		$1.97M Buy
+215,644
New +$2.2M ﹤0.01% 1614
2020
Q1 		– Sell
-91,948
Closed -$2.16M – 2597
2019
Q4 		$2.16M Sell
91,948
-45,260
-33% -$1M ﹤0.01% 1830
2019
Q3 		$2.58M Sell
137,208
-30,745
-18% -$566K ﹤0.01% 1725
2019
Q2 		$3.12M Sell
167,953
-950,032
-85% -$19M ﹤0.01% 1707
2019
Q1 		$27.3M Buy
1,117,985
+51,722
+5% +$1.35M 0.03% 632
2018
Q4 		$27.5M Sell
1,066,263
-821,128
-44% -$22.6M 0.03% 577
2018
Q3 		$59.7M Buy
1,887,391
+1,721,947
+1,041% +$64.1M 0.05% 380
2018
Q2 		$6.43M Buy
165,444
+57,518
+53% +$1.83M 0.01% 1434
2018
Q1 		$2.98M Sell
107,926
-1,665
-2% -$37.8K ﹤0.01% 1750
2017
Q4 		$1.98M Sell
109,591
-117
-0.1% -$1.91K ﹤0.01% 2019
2017
Q3 		$1.77M Buy
109,708
+51
+0% +$800 ﹤0.01% 2050
2017
Q2 		$1.52M Buy
109,657
+16,429
+18% +$238K ﹤0.01% 2079
2017
Q1 		$1.41M Sell
93,228
-300
-0.3% -$4.15K ﹤0.01% 2122
2016
Q4 		$1.23M Sell
93,528
-74,441
-44% -$1.17M ﹤0.01% 2146
2016
Q3 		$2.88M Sell
167,969
-46,922
-22% -$871K ﹤0.01% 1844
2016
Q2 		$3.88M Sell
214,891
-257,787
-55% -$5.03M ﹤0.01% 1625
2016
Q1 		$8.98M Buy
472,678
+25,787
+6% +$509K 0.01% 1181
2015
Q4 		$12.2M Buy
446,891
+289,936
+185% +$7.75M 0.01% 974
2015
Q3 		$3.83M Sell
156,955
-282,185
-64% -$9.4M ﹤0.01% 1384
2015
Q2 		$13.7M Sell
439,140
-515,640
-54% -$9.7M 0.01% 960
2015
Q1 		$13.9M Buy
+954,780
New +$10.8M 0.02% 823

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Allianz Asset Management's HRTX Position: Q2 2022 in Review

Allianz Asset Management sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 155,085 shares — an estimated $887K sold.

Allianz Asset Management first reported a position in HRTX in Q1 2015 and held it in 22 quarters. The position peaked at $59.7M in Q3 2018. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • Allianz Asset Management reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Allianz Asset Management sold 155,085 Heron Therapeutics shares in Q2 2022, an estimated $887K.
  • Allianz Asset Management first reported a position in Heron Therapeutics in Q1 2015 and held it in 22 quarters.
  • Allianz Asset Management's Heron Therapeutics position peaked at $59.7M in Q3 2018.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Allianz Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.